BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
Status:
Terminated
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of
Intravenously Infused BIIB092 in Patients with Four Different Primary Tauopathy Syndromes